← Back to Clinical Trials
Recruiting NCT04252781

NCT04252781 Incident Chronic Obstructive pulmoNary dIsease Cohort Study (ICONIC)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04252781
Status Recruiting
Phase
Sponsor Assistance Publique - Hôpitaux de Paris
Condition Smokers
Study Type INTERVENTIONAL
Enrollment 300 participants
Start Date 2020-08-20
Primary Completion 2025-01-07

Eligibility & Interventions

Sex All sexes
Min Age 35 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Exhaustive exploration

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 300 participants in total. It began in 2020-08-20 with a primary completion date of 2025-01-07.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Chronic Obstructive Pulmonary Disease (COPD), , secondary to smoking, is a major public health issue with very high direct and indirect costs. The impact on the health system of undiagnosed patients, up to 70% of patients, is increasingly documented. However, systematic spirometry screening remains controversial among smokers in the absence of data to link the detection of new patients with improved management and clinical events and health goals. More generally, there is little data on the evolution of patients in real life once they have entered the care system. The premise is that with systematic screening in general medicine, it is possible to identify the evolution of newly diagnosed COPD patients, to distinguish the different possible evolutions according to the initial phenotype and the management.

Eligibility Criteria

Inclusion Criteria: Inclusion criteria of smokers with spirometry (pre-inclusion) * Age\> 35 years * Smoking \> 20 PA * Active smoking (cessation \< 1 month) * Signature of consent to participate in Phase I of the study Inclusion criteria for patients with incidental COPD * FEV1 / FVC \<70% of the theoretical value and / or \<LLN (Lower limit of normal) * Signature of consent to participate in Phase II of the study Exclusion Criteria: * Known COPD * Cancer being treated * No affiliation to the social security or other social protection scheme * Pregnant or lactating woman * Patient deprived of liberty or under legal protection (under tutorship or curatorship

Contact & Investigator

Central Contact

Laurent BOYER, MD

✉ laurent.boyer@aphp.fr

📞 (0) 1 49 81 26 90

Principal Investigator

Laurent BOYER, MD

PRINCIPAL INVESTIGATOR

Assistance Publique Hôpitaux de Paris (AP-HP)

Frequently Asked Questions

Who can join the NCT04252781 clinical trial?

This trial is open to participants of all sexes, aged 35 Years or older, studying Smokers. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04252781 currently recruiting?

Yes, NCT04252781 is actively recruiting participants. Contact the research team at laurent.boyer@aphp.fr for enrollment information.

Where is the NCT04252781 trial being conducted?

This trial is being conducted at Créteil, France.

Who is sponsoring the NCT04252781 clinical trial?

NCT04252781 is sponsored by Assistance Publique - Hôpitaux de Paris. The principal investigator is Laurent BOYER, MD at Assistance Publique Hôpitaux de Paris (AP-HP). The trial plans to enroll 300 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology